DRX9000 Spinal Decompression

Archive for the ‘back pain relief news’ Category

[Treatment of 94 Outpatients With Chronic Discogenic Low Back Pain with the DRX9000: A Retrospective Chart Review. From the Wiley Online Library.

Citation: Macario, A., Richmond, C., Auster, M. and Pergolizzi, J. V. (2008), Treatment of 94 Outpatients With Chronic Discogenic Low Back Pain with the DRX9000: A Retrospective Chart Review. Pain Practice, 8: 11–17. doi: 10.1111/j.1533-2500.2007.00167.x
]

Methods: Patients at a convenience sample of four clinics received 30-minute DRX9000. sessions daily for the first 2 weeks tapering to 1 session/week. Treatment protocol included lumbar stretching, myofascial release, or heat prior to treatment, with ice and/or muscle stimulation afterwards. Primary outcome was verbal numerical pain intensity rating (NRS) 0 to 10 before and after the 8-week treatment.

Results: Of the 100 initial subjects, three withdrew their protected health information, and three were excluded because their LBP duration was less than 12 weeks. The remaining 94 subjects (63% female, 95% white, age = 55 (SD 16) year, 52% employed, 41% retired, LBP median duration of 260 weeks) had diagnoses of herniated disc (73% of patients), degenerative disc disease (68%), or both (27%). Mean NRS equaled 6.05 (SD 2.3) at presentation and decreased significantly to 0.89 (SD 1.15) at end of 8-week treatment (P < 0.0001). Analgesic use also appeared to decrease (charts with data = 20) and Activities of Daily Living improved (charts with data = 38). Follow-up (mean 31 weeks) on 29/94 patients reported mean 83% LBP improvement, NRS of 1.7 (SD 1.15), and satisfaction of 8.55/10 (median 9).

Conclusions: This retrospective chart audit provides preliminary data that chronic LBP may improve with DRX9000 spinal decompression. Randomized double-blind trials are needed to measure the efficacy of such systems. 

[Click to view the full DRX9000 low back pain chart review article.]

[In a study of 50 patients, Dr. Noriaki Yamamoto and others reported that 76% of patients were satisfied with the treatment they received using the DRX9000. This study was not sponsored by Axiom Worldwide, the manufacturer of the DRX9000 spinal decompression system.]

Japanese study reports 76% of patients were satisfied after treatment on the DRX-9000!

Tampa, FL, April 30, 2009: A study titled, “The treatment of lumbar disc disease using DRX-9000” is published in the December issue of the Nigata University Journal of Health and Welfare. After treating fifty patients on the DRX-9000, Dr. Noriaki Yamamoto and others reported that 76% of patients were satisfied with the treatment. The patients received 30-minute sessions every week or 2 weeks, for 3 months and revealed a decrease in pain of 4.91 ± 0.93 to 2.69 ± 1.02 (p<0.01). Although the treatment program used by Dr. Yamamoto did not follow Axiom’s published protocol, positive results were still demonstrated. A previous study following Axiom’s protocol which was published in the December 2008 issue of the Journal of Medicine revealed a mean patient rating of 7.61 (0-10 scale) at the mid point of treatment and 8.1 after the final week of treatment. To review additional clinical studies please go to www.axiomworldwide.com/research.aspx.

The foregoing study was not sponsored by Axiom Worldwide. Axiom has made no determination of and makes no representations as to the design, scope or manner in which the study was conducted. Axiom Worldwide’s referencing the presentation of the study should not be construed to mean that Axiom Worldwide represents that the study establishes any conclusive success rate or the efficacy of the device. The information is offered simply to demonstrate the exciting activity ongoing with the DRX9000. As always, individual patient’s experiences with the DRX9000 may vary and patients should always consult with their physician to determine whether treatment on the DRX9000 makes sense for them.

Axiom Worldwide manufactures and distributes its flagship products, the DRX9000 True Non-surgical Spinal Decompression System™ and DRX9000C™ in medical markets around the globe. Axiom also manufactures a digital electroceutical device, the EPS8000™, for use in relieving pain and for use in muscular rehabilitation. Axiom prides itself on providing safe, non-surgical alternatives that patients should consider prior to undergoing surgery. For additional information please visit: www.AxiomWorldwide.com. To schedule an interview please contact: Amber Pacetti, Marketing at: telephone: 001-813-249-6444 or email: apacetti@axiomworldwide.com.

[Business Wire press release from Axiom Worldwide of Florida, makers of the popular DRX9000 and DRX9000C line of spinal decompression systems. Clinical data on the DRX9000 will be presented at the CONy in Greece.]

Clinical Data Utilizing the DRX9000(TM) Will Be Presented at the CONy in Athens, Greece!
Friday October 10, 5:13 pm ET

TAMPA, Fla.–(BUSINESS WIRE)–Clinical data utilizing the DRX9000 True Non-Surgical Spinal Decompression System™ will be presented at the 2nd World Congress on Controversies in Neurology (CONy) in Athens, Greece October 23-26, 2008. The first study, is an IRB-approved, prospective multi-center phase II, non-randomized pilot study authored by Dr. John Leslie of the Mayo Clinic and others. This study was designed to evaluate the effectiveness and safety of the DRX9000 in treating chronic LBP [lower back pain]. A greater than 50% reduction in pain score was observed after two weeks of treatment and upon completion of the entire six week protocol an amazing success rate of 88.9% was documented. Improvement of Oswestry scores and a decreased consumption of adjunctive pain medication were also noted. The second study, is retrospective data which included lumbar spine CT scans before and after patients were treated on the DRX9000 that demonstrates possible morphological changes associated with treatment. The authors conclude, “A significant reduction in chronic LBP after non-invasive spinal decompression correlated with an increase in disc height.” One of the authors of the studies will be presenting the data at the 2nd World Congress CONy. Abstracts of both studies will be available. These presentations represent an effort to further educate the International Community on the effectiveness of our products.

Non-treatment or control groups were not included making efficacy outcome versus placebo or spontaneous recovery difficult to determine. Randomized double-blinded or comparative long-term outcome trials are needed to further prove the efficacy of non-surgical spinal decompression systems such as the DRX9000™ for the routine treatment of chronic LBP. This study was partially funded by Axiom Worldwide.

A randomized controlled trial is needed to prove that restoration in disc height is the mechanism through which non-surgical spinal decompression systems such as the DRX9000™ leads to these impressive reductions in pain.

Axiom Worldwide manufactures and distributes its flagship products, the DRX9000 True Non-surgical Spinal Decompression System™, DRX9000C™, and DRX9500™ in medical markets around the globe. Axiom also manufactures a digital electroceutical device, the EPS8000™, for use in relieving pain and for use in muscular rehabilitation. Axiom prides itself on providing safe, non-surgical alternatives that patients should consider prior to undergoing surgery. For additional information please visit: www.AxiomWorldwide.com.

To schedule an interview please contact: Amber Pacetti, Marketing at: telephone: 001-813-249-6444 or email: apacetti@axiomworldwide.com.

Contact:

Axiom Worldwide, Tampa
Amber Pacetti, 813-249-6444